The T-type Ca2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs

Circulation

Volumn 100, Issue 21, 1999, Pages 2191-2197

  Fareh, Samir ^a   Bénardeau, Agnès ^a,c   Thibault, Bernard ^a   Nattel, Stanley ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antiarrhythmia agents; Arrhythmia; Calcium channels; Electrophysiology

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA;

EID: 0345440145     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.21.2191     Document Type: Article

References (27)

1. Kannel WB, Wolf PA. Epidemiology of atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York, NY: Raven Press Publishers; 1992:81-92.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018-1022.
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998;98:946-952.
4. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J. 1995;130:1094-1106.
5. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, Frye RL, The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317: 669-674.
6. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91: 1588-1595.
7. Nattel S. Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation. Cardiovasc Res. 1999;42:298-308.
8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
9. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: electrophysiological remodeling. Circulation. 1996;94:2954-2960.
10. Goette A, Honeycutt C, Langberg JL. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94: 2968-2974.
11. Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, Morady F. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation. 1996;94:1600-1606.
12. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation. 1997;96:4027-4035.
13. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced electrical remodeling. Circulation. 1998;98: 2202-2209.
14. Daoud EG, Knight BP, Weiss R, Bahu M, Paladino W, Goyal R, Man KC, Strickberger SA, Morady F. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 1997;96:1542-1550.
15. Yu WC, Chen SA, Lee SH, Tai CT, Feng AN, Kuo BIT, Ding YA, Chang MS. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 1998; 97:2331-2337.
16. Tieleman RG, De Langen CDJ, van Gelder IC, de Kam PJ, Grandjean J, Bel KJ, Wijffels MCEF, Alessie MA, Crijns HJGM. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997; 95:1945-1953.
17. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512-525.
18. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
19. 2+ channels. J Pharmacol Exp Ther. 1994;271:1483-1488.
20. 2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther. 1997;11:723-739.
21. Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation. 1996;93:1747-1754.
22. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157-3163.
23. 2+ channel gene family. Circ Res. 1998;83:103-109.
24. Abernethy DR. Pharmacologic and pharmacokinetic profile of mibefradil, a T-and L-type calcium channel antagonist. Am J Cardiol. 1997;80: 4C-11C.
25. Zipes DP. Atrial fibrillation: a tachycardia-induced atrial cardiomyopathy. Circulation. 1997;95:562-564.
26. Waktare JE, Camm AJ. Atrial fibrillation begets trouble. Heart. 1997;77: 393-394.
27. Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet. 1998;351:1829-1830.